Exelixis
EXEL
S$56.39
Share price
1.56%
Change (1 day)
88.11%
Change (1 year)
Categories
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.
Exelixis (EXEL) - Total assets
Total assets on the balance sheet as of March 2025 : S$3.61 Billion
According to Exelixis's latest financial reports the company's total assets are S$3.61 Billion. A company’s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.
Exelixis - Total assets on balance sheet (from 2001 to 2025)
Total assets by year
| Year | Total assets | Change |
|---|---|---|
| 2024-12-31 | S$4.00 B | 3.11% |
| 2023-12-31 | S$3.88 B | -5.63% |
| 2022-12-31 | S$4.11 B | 16.42% |
| 2021-12-31 | S$3.53 B | 25.09% |
| 2020-12-31 | S$2.82 B | 11.22% |
| 2019-12-31 | S$2.54 B | 30.84% |
| 2018-12-31 | S$1.94 B | 121.69% |
| 2017-12-31 | S$0.87 B | 1.65% |
| 2016-12-31 | S$0.86 B | 83.41% |
| 2015-12-31 | S$0.47 B | 10.06% |
| 2014-12-31 | S$0.42 B | -33.01% |
| 2013-12-31 | S$0.63 B | -27.69% |
| 2012-12-31 | S$0.88 B | 73.15% |
| 2011-12-31 | S$0.50 B | 9.59% |
| 2010-12-31 | S$0.46 B | -3.6% |
| 2009-12-31 | S$0.48 B | -16.06% |
| 2008-12-31 | S$0.57 B | -3.15% |
| 2007-12-31 | S$0.59 B | -2.19% |
| 2006-12-31 | S$0.60 B | 9.45% |
| 2005-12-31 | S$0.55 B | 16.55% |
| 2004-12-31 | S$0.47 B | -21.81% |
| 2003-12-31 | S$0.60 B | 3.31% |
| 2002-12-31 | S$0.58 B | -8.3% |
| 2001-12-31 | S$0.64 B |
Total Assets for similar companies or competitors
| Company | Total assets | differencediff. | Country |
|---|---|---|---|
 GlaxoSmithKline GSK | S$99.83 B | 2,664.52% | 🇬🇧 UK |
 Sanofi SNY | S$181.61 B | 4,929.24% | 🇫🇷 France |
 Merck MRK | S$146.52 B | 3,957.52% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | S$117.64 B | 3,157.63% | 🇺🇸 USA |
 Amgen AMGN | S$113.74 B | 3,049.78% | 🇺🇸 USA |
 Johnson & Johnson JNJ | S$246.50 B | 6,726.01% | 🇺🇸 USA |
 Pfizer PFE | S$264.77 B | 7,232.03% | 🇺🇸 USA |
 Curis CRIS | S$50.05 M | -98.61% | 🇺🇸 USA |
 AVEO Oncology
AVEO | S$0.12 B | -96.43% | 🇺🇸 USA |